DE60329211D1 - Cytarabin-monophosphate prodrugs - Google Patents

Cytarabin-monophosphate prodrugs

Info

Publication number
DE60329211D1
DE60329211D1 DE60329211T DE60329211T DE60329211D1 DE 60329211 D1 DE60329211 D1 DE 60329211D1 DE 60329211 T DE60329211 T DE 60329211T DE 60329211 T DE60329211 T DE 60329211T DE 60329211 D1 DE60329211 D1 DE 60329211D1
Authority
DE
Germany
Prior art keywords
cytarabin
monophosphate prodrugs
cytarabine
prodrugs
monophosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329211T
Other languages
German (de)
English (en)
Inventor
Serge H Boyer
Mark D Erion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of DE60329211D1 publication Critical patent/DE60329211D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60329211T 2002-10-31 2003-10-31 Cytarabin-monophosphate prodrugs Expired - Lifetime DE60329211D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42321102P 2002-10-31 2002-10-31
US42325902P 2002-10-31 2002-10-31
PCT/US2003/034690 WO2004041837A1 (en) 2002-10-31 2003-10-31 Novel cytarabine monophosphate prodrugs

Publications (1)

Publication Number Publication Date
DE60329211D1 true DE60329211D1 (de) 2009-10-22

Family

ID=32314479

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329211T Expired - Lifetime DE60329211D1 (de) 2002-10-31 2003-10-31 Cytarabin-monophosphate prodrugs

Country Status (13)

Country Link
US (4) US7151092B2 (enExample)
EP (2) EP1556393B1 (enExample)
JP (2) JP5046219B2 (enExample)
KR (2) KR101115210B1 (enExample)
AT (1) ATE442375T1 (enExample)
AU (2) AU2003287389B2 (enExample)
BR (2) BR0315795A (enExample)
CA (2) CA2503729C (enExample)
DE (1) DE60329211D1 (enExample)
IL (2) IL167984A (enExample)
MX (2) MXPA05004504A (enExample)
PL (2) PL376474A1 (enExample)
WO (2) WO2004041834A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU2003235501A1 (en) * 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL376474A1 (en) * 2002-10-31 2005-12-27 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
MXPA06014013A (es) 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
EP1915053A2 (en) * 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
US20070241502A1 (en) * 2006-04-14 2007-10-18 Campbell Darrell C Poker game and apparatus for play thereof
US7584968B2 (en) * 2006-04-14 2009-09-08 Seven Generations, Inc. Poker game and apparatus for play thereof
WO2009073506A2 (en) * 2007-11-29 2009-06-11 Metabasis Therapeutics Inc. Nucleoside prodrugs and uses thereof
TW200936146A (en) * 2007-11-29 2009-09-01 Metabasis Therapeutics Inc Antiviral nucleoside compounds
WO2009134405A2 (en) * 2008-04-30 2009-11-05 Siemens Medical Solutions Usa, Inc. Novel substrate based pet imaging agents
CN101787064B (zh) * 2009-01-23 2013-03-13 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
JP5631414B2 (ja) * 2010-01-15 2014-11-26 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ホスホ置換アルコキシアミン化合物
WO2011113174A1 (zh) * 2010-03-15 2011-09-22 Gao Feng 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
PT3013351T (pt) * 2013-06-24 2020-01-17 Canbas Co Ltd Péptidos e peptidomiméticos em utilizações e tratamentos combinados para subpopulações de pacientes com cancro
GB201317166D0 (en) * 2013-09-27 2013-11-06 Astex Therapeutics Ltd Pharmaceutical compounds
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
JP7149183B2 (ja) 2015-12-03 2022-10-06 バイオサイト リミテッド 癌治療のためのシタラビンコンジュゲート
EP3383883A4 (en) * 2015-12-03 2019-07-24 BioSight Ltd. SALTS OF CONJUGATES TO CANCER THERAPY
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
JP6775591B2 (ja) * 2016-09-20 2020-10-28 株式会社島津製作所 両親媒性ブロックポリマーを用いた薬剤内包分子集合体
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
CN109956985A (zh) 2017-12-22 2019-07-02 浙江柏拉阿图医药科技有限公司 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE554888A (enExample) * 1956-12-20
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3328388A (en) 1964-09-02 1967-06-27 Merck & Co Inc Arabinofuranosyl pyrimidines and methods of preparing same
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
US4749694A (en) 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US4973579A (en) * 1985-06-28 1990-11-27 Merck & Co., Inc. Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4822773A (en) 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4963556A (en) * 1985-08-16 1990-10-16 Merck & Co., Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4847298A (en) * 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4963525A (en) 1985-08-16 1990-10-16 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US5159067A (en) 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
DE68924456T2 (de) 1988-08-02 1996-05-30 Nissan Chemical Ind Ltd Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel.
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
WO1993016388A1 (en) * 1992-02-13 1993-08-19 The Uab Research Foundation Method of detecting and monitoring levels of 3'-amino-3'-deoxythymidine in body fluids and antibodies for same
GB2266527A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
GB2266525A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia
AU685128B2 (en) 1993-05-21 1998-01-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
DE69426904T2 (de) * 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
ATE486882T1 (de) 1993-09-17 2010-11-15 Gilead Sciences Inc Nukleotidanaloge
US5437772A (en) 1993-11-01 1995-08-01 The Electrosynthesis Co., Inc. Portable lead detector
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6130504A (en) * 1997-07-11 2000-10-10 Sharp Kabushiki Kaisha Plasma addressing display device and method for producing the same
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2322487C (en) * 1998-03-06 2010-07-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6395716B1 (en) 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CA2348470C (en) * 1998-11-05 2007-06-05 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis b virus activity
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
SK12442001A3 (sk) 1999-03-05 2002-06-04 Metabasis Therapeutics, Inc. Cyklické fosforamidáty, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
JP4979866B2 (ja) * 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
EP1253921A4 (en) * 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
CA2400197A1 (en) 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
DE60105424T2 (de) 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
BR0208790A (pt) * 2001-04-11 2004-03-30 Idenix Cayman Ltd Fenilindoìs para o tratamento de hiv
US20030232760A1 (en) * 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
PL376474A1 (en) 2002-10-31 2005-12-27 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs

Also Published As

Publication number Publication date
AU2003287389A1 (en) 2004-06-07
CA2503729A1 (en) 2004-05-21
CA2503730A1 (en) 2004-05-21
US20040092476A1 (en) 2004-05-13
US20070037774A1 (en) 2007-02-15
US7553826B2 (en) 2009-06-30
WO2004041834A3 (en) 2004-07-01
CA2503729C (en) 2012-09-18
AU2003287389B2 (en) 2010-08-12
EP1556398A1 (en) 2005-07-27
EP1556393B1 (en) 2013-12-25
JP2006504791A (ja) 2006-02-09
JP5046219B2 (ja) 2012-10-10
PL376327A1 (en) 2005-12-27
MXPA05004503A (es) 2005-08-16
ATE442375T1 (de) 2009-09-15
US7498320B2 (en) 2009-03-03
AU2003286816A1 (en) 2004-06-07
EP1556398B1 (en) 2009-09-09
KR101115210B1 (ko) 2012-04-12
KR20050072776A (ko) 2005-07-12
KR101026294B1 (ko) 2011-03-31
PL376474A1 (en) 2005-12-27
PL212929B1 (pl) 2012-12-31
US7151092B2 (en) 2006-12-19
KR20050083879A (ko) 2005-08-26
JP2006507308A (ja) 2006-03-02
WO2004041837A1 (en) 2004-05-21
BR0315806A (pt) 2005-09-13
US20070021388A1 (en) 2007-01-25
AU2003286816B2 (en) 2010-08-19
MXPA05004504A (es) 2005-08-16
CA2503730C (en) 2011-10-18
EP1556393A2 (en) 2005-07-27
IL167990A (en) 2010-12-30
IL167984A (en) 2011-09-27
US20040192651A1 (en) 2004-09-30
JP4689274B2 (ja) 2011-05-25
BR0315795A (pt) 2005-09-13
US7148349B2 (en) 2006-12-12
WO2004041834A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
ATE442375T1 (de) Cytarabin-monophosphate prodrugs
AP2002002637A0 (en) Novel piperazine
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
SE9504661D0 (sv) New compounds
TR200201144T2 (tr) NFKB aktivitesinin modülasyonu için ikame edilmiş indoller
NO920298D0 (no) 2,3,6-substituerte kinazolinoner
EP1442016A4 (en) 1H-INDOLDERIVATE AS HIGH-DETECTIVE CYCLOOXYGENASE-2 INHIBITORS
DE60208355D1 (de) 2-amino-propanol derivate
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
MY135841A (en) Novel benzodioxoles
NO20026253D0 (no) Organiske forbindelser
AR038427A2 (es) Compuestos 15-alquil-14-hidroxilo de marcfortina y parahercuamida
TR200400238T4 (tr) ''Perindopril tert-bütilamin tuzunun alfa kristalin şekli''
ATE233274T1 (de) Oxyiminopregnancarbolactone
TR200103460T2 (tr) 5-Fenil-pirimidin türevleri
YU17301A (sh) KRISTALNI OBLICI EtO2C-CH2-(R)-Cgl-Aze-Pab-OH
ATE219073T1 (de) Benzopyran derivate mit leukotrien- antagonistischer wirkung
AP2001002306A0 (en) Bridged piperazine derivatives.
DE69903053D1 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DK1056754T3 (da) Phosphatderivater af diaryl-1,3,4-oxadiazolon
TR200300551T2 (tr) Agrokimyasal kompozisyon
TR200102334T2 (tr) Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition